甲状腺功能亢进性不孕 中国就医指南

Hyperthyroidism-associated infertility refers to impaired reproductive capacity—specifically, difficulty conceiving or sustaining pregnancy—resulting from uncontrolled or suboptimally managed hyperthyroidism. This condition arises when excessive thyroid hormone production (primarily thyroxine [T4] and triiodothyronine [T3]) disrupts the hypothalamic–pituitary–gonadal (HPG) axis, leading to menstrual irregularities (e.g., oligomenorrhea, amenorrhea), anovulation, luteal phase defects, and reduced ovarian reserve in women; in men, it may cause decreased libido, erectile dysfunction, and impaired spermatogenesis. Autoimmune Graves’ disease accounts for ~85% of cases, while toxic nodular goiter and thyroiditis contribute to the remainder. Pathophysiologically, elevated T3/T4 suppresses gonadotropin-releasing hormone (GnRH) pulse frequency, lowers follicle-stimulating hormone (FSH) and luteinizing hormone (LH) secretion, alters sex hormone-binding globulin (SHBG) levels, and increases estrogen metabolism—collectively impairing folliculogenesis and endometrial receptivity. Epidemiologically, hyperthyroidism affects ~1–2% of women of reproductive age globally, with infertility reported in up to 30–40% of untreated or poorly controlled patients. Risk factors include female sex, age 25–45 years, personal or family history of autoimmune thyroid disease (e.g., Hashimoto’s, type 1 diabetes), iodine excess, smoking, and stress-induced immune dysregulation. Importantly, subclinical hyperthyroidism—often overlooked—can also compromise fertility outcomes, particularly in assisted reproductive technology (ART) cycles. Quality of life is significantly impacted: patients frequently report fatigue, anxiety, insomnia, palpitations, weight loss, and emotional distress—all of which compound reproductive stress and reduce treatment adherence. Moreover, untreated hyperthyroidism during early pregnancy increases risks of miscarriage, preterm birth, fetal growth restriction, and maternal heart failure. Timely diagnosis—via sensitive TSH, free T4, free T3, and thyroid autoantibody (TRAb, TPOAb) testing—is critical. Fertility preservation strategies must integrate endocrine stabilization (e.g., antithyroid drugs, radioiodine ablation with appropriate washout periods, or surgery) before initiating ovulation induction or IVF. Multidisciplinary care involving reproductive endocrinologists and thyroid specialists improves conception rates and live birth outcomes. With proper management, most patients regain normal fertility within months of euthyroid status restoration.

# 甲状腺功能亢进性不孕：治疗方案与费用明细（生殖医学科）

一、非手术/保守治疗方案

适用人群：甲亢未控制（FT3/FT4↑、TSH＜0.1 mIU/L）、伴排卵障碍或黄体功能不足者，无严重心肝肾并发症。

• •药物治疗（首选）：

- 费用：药费 80–300元/月；每月甲状腺功能（FT3/FT4/TSH）、性激素六项、超声监测排卵：620–980元

• •理疗辅助：心理干预+营养支持（碘摄入管理、硒补充）

二、手术/介入治疗方案

适用条件：药物过敏/失效、甲状腺显著肿大（＞40mL）或结节压迫致不孕持续＞12个月。

• •甲状腺次全切除术（开放）：术前需完成甲状腺彩超、ECT、喉镜、心肺功能评估

- 手术+麻醉+住院（7–10天）：28,000–42,000元（含术后TSH调控及生殖内分泌同步管理）

三、特殊复杂情况方案

耐药/复发/合并PCOS或子宫内膜容受性下降者：

• •131I治疗后联合IVF-ET（需甲功稳定≥3个月）

四、方案快速选择指南

• •预算＜1万元/年：优选药物+生殖内分泌联合管理（首年总控费约8,500元）
• •急迫妊娠需求（＞35岁）：直接启动甲功达标后IVF，避免延误窗口期
• •反复生化妊娠/胚胎停育：加做甲状腺抗体（TRAb）、凝血与免疫指标，费用上浮3,200–5,600元